Developing COVID-19 Vaccines in Record Time: Platforms and Partnerships for Prevention
May 12, 2020
Global health leaders have all said that the long-term solution to ending the pandemic is the arrival of a vaccine or vaccines that can be rapidly deployed around the world. Yet the development of a vaccine is a complex undertaking, especially during a global pandemic of an unknown pathogen with uncertain epidemiology. Even so, many vaccine developers moved swiftly, using platform technologies to go from genetic sequence data to vaccine candidates in a few short weeks, shortening typical timelines by months and years.
During this virtual meeting, the panel members shown below discussed the path to clinical trials and shared their thoughts on how collaboration will bring life-saving vaccines to the world in this time of unprecedented need.
Please check below to view a recording of the entire panel discussion or to access individual presentations shared during the meeting.
Developing COVID-19 Vaccines in Record Time
PANELISTS
- Introduction
Phyllis Arthur, MBA
Vice President, Infectious Diseases & Diagnostics Policy
BIO
- Advantages of DNA Vaccines in Response to COVID-19
Laurent M. Humeau, PhD
Chief Science Officer and EVP of Research, Engineering and Clinical Developments
Inovio
- Janssen Ad26/PER.C6® based COVID-19 (SARS-CoV-2) Vaccine Candidate
Macaya Douoguih, MD, MPH
Head of Clinical Development
Janssen Vaccines
- Moderna – Development of COVID-19 Vaccine
Mike Watson, MD
Consultant, Vaccines and Infectious Diseases
Moderna
- NVX-CoV2373 Vaccine for COVID-19
Greg Glenn, MD
President, Research and Development
Novavax
- BioNTech-Pfizer COVID-19 Vaccine Program
Philip Dormitzer, MD, PhD
Vice President and Chief Scientific Officer, Viral Vaccines
Pfizer
- Sanofi Pasteur: COVID-19 Candidate Vaccines
Clement Lewin, PhD, MBA
Associate Vice President, Head BARDA Office & NV Stakeholder Engagement
Sanofi Pasteur